Visit morningcommutepodcast.com/endometrial2 to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this activity, two experts on endometrial cancer discuss patient selection, toxicities, toxicity management, and how new therapies are entering into the clinical domain with increasing frequency.

In this episode, our faculty, Dr. Justin F. Gainor and Elizabeth A. Krueger, CNP, discuss practical and evidence-based strategies for managing patients with RET fusion-positive NSCLC. Learn about the defining pathologic features that distinguish this lung cancer, the recommended testing modalities for RET fusions, treatment selection, and how to manage adverse effects.

Visit https://suitehome.atpointofcare.com/library/2694.02/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this episode, our faculty, Dr. Charu Aggarwal and Beth Sandy, MSN, CRNP, FAPO, discuss biomarker testing, first-line treatment decisions, including some of the latest clinical data from the anaplastic lymphoma kinase (ALK) trials, and real-world strategies to manage toxicities in patients with ALK-positive NSCLC.

Visit https://suitehome.atpointofcare.com/library/2694.01/page/0?subdomain=nsclc to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss what clinicians need to know about optimizing treatment strategies for their patients with multiple myeloma. They explore approaches to bridging therapy to improve efficacy and reduce toxicity, evidence-based principles for sequencing B-cell maturation antigen (BCMA)-targeted agents, and how to navigate the challenge of prior BCMA exposure to improve patient outcomes. Visit https://suitehome.atpointofcare.com/library/2676.13/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

Visit http://journalclubpodcasts.com/cll to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit. In this Journal Club Podcast our expert faculty look at treatment of CLL patients with Covid-19, specifically BTK-inhibitors and monoclonal anti-CD20 antibodies.

In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, discuss patient selection. Who is the ideal candidate for chimeric antigen receptor (CAR) T-cell therapy? The latest evidence from ASH and Tandem meetings adds crucial data to patient selection strategies. Visit https://suitehome.atpointofcare.com/library/2676.12/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.

In this Journal Club episode, our Faculty, Dr. Joseph Mikhael and Dr. Krina Patel, explore shifting CAR T-cell therapy into earlier lines of treatment for patients with relapsed/refractory disease, and discuss treatment updates recently presented at ASH 2024 and the 2025 Tandem Meetings. ** Visit https://suitehome.atpointofcare.com/library/2676.11/page/0?subdomain=myeloma to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit**

In this episode, Staying the Course in Metastatic Breast Cancer, Dr. Joyce O’Shaughnessy and Marissa Marti-Smith talk about the importance of shared decision making and patient education. What do your patients need to know about the latest data on toxicities and toxicity management to help them better adhere to their treatment regimen?

Visit https://suitehome.atpointofcare.com/library/2685.03/page/0?subdomain=breastcancer to view the activity and CME/CE information, download the transcript, and complete the posttest and evaluation to earn CME/CE credit.